TrialAn Extension of Protocol PRO 140_CD01 Study
Trial details
- Registry ID
- NCT02355184
- Phase
- Phase 2
Drug research
PRO 140 350mg weekly subcutaneous (SC) injection.
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as PRO 140
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Extension of Protocol PRO 140_CD01 StudyNCT02355184 | CytoDyn, Inc. | Phase 2 | Terminated | 2022-06Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |